#Evoke

MikeDoustdar

Novo Nordisk halted a planned extension of its Alzheimer’s semaglutide study after the Evoke and Evoke-plus pills failed to reduce cognitive decline by 20% compared to a placebo. Mike Doustdar implemented a 10%...